

U54 NCI Drug Resistance and Sensitivity Center (DRSC):
University of California, San Francisco / Stanford University

Information for Potential Administrative Supplement Collaborators

Supplement Funding Announcement released April 11, 2018: Administrative Supplements to NCI Grant and Cooperative Agreement Awards to Support Collaborations with the Drug Resistance and Sensitivity Network (DRSN) (PAR-18-752): <https://grants.nih.gov/grants/guide/pa-files/PAR-18-752.html>.

Section 1: Bay Area Team Against Resistance, UCSF/Stanford: Current DRSN-related research projects

Overarching DRSC Study Title: Bay Area Team Against Resistance
<p>Primary Contact for Collaborative Supplement Inquiries</p> <p>Name/Title: Collin Blakely MD PhD Institution: UCSF Email: Collin.blakely@ucsf.edu Phone: n/a</p>
Research Project 1 Title: Overcoming residual disease in lung cancers treated with targeted therapy
Project 1 Summary: This project seeks to define mechanisms of residual disease that promote resistance to targeted therapy in lung cancer, to identify new targets for intervention to enhance clinical outcomes.
Project 1 scientific assays and models used: patient-derived organoid and PDX models, cell signaling analysis, RNAseq, proteomics, CRISPR-based gene perturbations, clinical specimens
<p>Project 1 Lead:</p> <p>Name/Title: Trever Bivona MD PhD Institution: UCSF Email: trever.bivona@ucsf.edu</p>
Research Project 2 Title: Overcoming residual disease in lung cancers treated with immunotherapy
Project 2 Summary: This project seeks to define mechanisms of residual disease that promote resistance to immune checkpoint inhibitor therapy in lung cancer, to identify new targets for intervention to enhance clinical outcomes.
Project 2 scientific assays and models used: patient-derived organoid and PDX models, cell signaling analysis, RNAseq, proteomics, CRISPR-based gene perturbations, clinical specimens
<p>Project 2 Lead</p> <p>Name/Title: Calvin Kuo MD PhD Institution: Stanford University Email: cjkuo@stanford.edu</p>

Section 2: DRSC information for a potential collaborative supplement study

Types of assays, technologies, or model systems that our DRSC would be willing to utilize and/or share with other researchers in cancer drug resistance, who might be a recipient of a DRSN supplement award:

patient-derived organoid and PDX models, cell signaling analysis, RNAseq, proteomics, CRISPR-based gene perturbations, clinical specimens

Our DRSC limits to collaborative interactions or assistance to supplement awardees:

N/A

Optimal year(s) for a collaborative supplement study with our DRSC (i.e., 2018, 2019, 2020, 2021, 2022):

Any year

Otherwise, any year would be acceptable with our DRSC, which is preferred by NCI to allow more flexibility for supplement studies:

Suggestions to potential supplement applicants:

Please contact us to initiate discussions around potential collaborations. Our DRSC would welcome such discussions and interactions.